1932

Abstract

Pregnant women are almost always excluded from randomized controlled clinical trials, as the risks to the fetus posed by most new chemical entities or approved drugs cannot be sufficiently ruled out. Hence, a major scientific challenge in this field is to discover and validate alternative tools that will fill the knowledge gap created by the lack of participation in gold-standard randomized trials. This review focuses on novel tools that allow estimation of fetal risks after exposure to therapeutic agents, such as placental perfusion studies, biomarkers of fetal exposure, and novel epidemiological and pharmacogenetic tools, all of which have been tested successfully in recent years.

Keyword(s): biomarkersfetusplacentarisksteratology
Loading

Article metrics loading...

/content/journals/10.1146/annurev-pharmtox-011613-135930
2014-01-06
2024-06-14
Loading full text...

Full text loading...

/content/journals/10.1146/annurev-pharmtox-011613-135930
Loading
/content/journals/10.1146/annurev-pharmtox-011613-135930
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error